Prediction: Won't Recognize Enbridge in 15 Years: What Changes the Story
As energy markets shift, a bold forecast asks whether Enbridge will look the same in 15 years. This analysis breaks d...
Articles — Page 163
Donald Trump Launches Quantum Push with Two Executive Orders
The White House signed two executive orders Friday to accelerate quantum research and shield federal data from future...
Demand Becomes the Swing Factor for Builders' Undersupply
In mid-2026, demand dynamics are reasserting themselves as the key driver behind housing trends. With supply still co...
Intel Drop, Nvidia Slips in Korea-Led Chip Selloff
A Korea-led chip selloff pulled AMD and Intel lower while Nvidia slipped, prompting analysts to frame the move as hea...
Three Defensive Anchors for Investors with $1.5 Million
As markets adjust to higher-for-longer rates, three Dividend Kings stand out as defensive anchors for a $1.5 million ...
Over Analysts Rate Buy: AMD's Bull Case Gains Momentum
More than 40 analysts now rate AMD a Buy as AI-driven data center demand fuels growth. Here’s why the stock could pus...
Forget Super Micro Computer: Buy This AI Hardware Stock Now
As AI server demand remains robust, one legacy tech giant stands out as a buy-after-pullback play. This piece weighs ...
Prediction: Chevron Could Drop as Oil Slips in Markets
Oil weakness adds pressure on Chevron as analysts weigh earnings visibility and cash returns. A rising risk of a drop...
Wall Street Fixated Wrong: A Trillion-Dollar Cash Engine Is a Buy
A tech giant lanes three high-margin engines—cloud, ads, and subscriptions—on a profitable retail base, challenging m...
MAGY Magnificent Seven Income ETF Expands Monday Payouts
MAGY, the MAGY Magnificent Seven Covered Call ETF, now offers a Monday-morning income payout. The fund uses an active...
Social Security Retirees Looking at a Big COLA Rise in 2027
Inflation fuels expectations for a sizable 2027 COLA. If the projection holds, social security retirees looking ahead...
Pfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...